Navigation Links
Two Phase III clinical trials on corifollitropin alfa (Org 36286),reach randomization target

OSS, the Netherlands, June 27, 2007-Organon, the human healthcare business unit of Akzo Nobel, announced today that two out of three Phase III clinical trials with corifollitropin alfa (Org 36286), a new long-acting fertility hormone, have reached their randomization target.

Corifollitropin alfa is a new recombinant fertility hormone. It is the first of a new class of gonadotropins (a sustained follicular stimulant or SFS) of which, due to its long half-life, one single injection may replace the first 7 injections with conventional gonadotropins during a fertility treatment cycle.

The objective of the ENGAGE trial, the largest double-blind fertility trial ever performed, is to demonstrate clinical efficacy and safety of corifollitropin alfa 150 µg in a double-blind comparison with Organon’s Puregon®, one of the most commonly used preparations to treat infertile patients. The recruitment goal of the ENGAGE trial was to include a total of 1400 patients from 34 fertility clinics in Europe, USA and Canada and was started in July, 2006. The study reached its randomization target on June 10, 2007.

A second trial, the ENSURE trial, is an efficacy and safety trial with corifollitropin alfa 100 µg designed specifically for women who weigh less than 60 kg (133 lbs). This double-blind study comparing corifollitropin alfa with Puregon® was started in January 2007 in 19 clinical trial centers in Europe and Asia with a recruitment goal of 330 patients by June 30, 2007. All 330 subjects have now been randomized.

David Nicholson, executive vice-president Research and Development at Organon commented: “The enthusiasm and dedication of investigators and staff involved in these trials was decisive in reaching our recruitment targets.”

A third Phase III trial in the LIFE program (the TRUST trial) focuses on safety of repeated treatments with corifollit
'"/>




Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:5/21/2013)... 2013 Kepner-Tregoe (KT), the global capability ... veteran Chris Geraghty has ... more than 20 years serving the industrial sector, ... He succeeds Ray Baxter , ... of the Board and CEO. ...
(Date:5/21/2013)... , May 21, 2013  Armada Health ... of the new Armada corporate website ( www.armadahealthcare.com ... communicate Armada,s unique and first-to-market services and its ... focused on the specialty pharmacy industry. ... of the Armada business model in delivering an ...
(Date:5/21/2013)... May 21, 2013 Hurel Corporation ("Hurel"), a ... cell-based assay platforms, today announced the appointment of ... the Company,s Board of Directors. Dr. MacDonald is the ... Schering-Plough Research Institute ("SPRI"), which was the pharmaceutical development ... Merck & Co. in 2009. Over a ...
Breaking Medicine Technology:Kepner-Tregoe, Inc. Promotes Chris Geraghty to Chief Executive Officer 2Kepner-Tregoe, Inc. Promotes Chris Geraghty to Chief Executive Officer 3Armada Announces New Corporate Website to Showcase Expanded Services to Specialty Pharmacy Marketplace 2Hurel Corporation Appoints Leading Pharmaceutical Executive and Toxicologist Dr. James S. MacDonald to Board of Directors 2
(Date:5/21/2013)... May 21, 2013 ContinuCare Home Health, ... Department of Aging and Disability Services. After completing a ... interviews, ContinuCare Home Health was found to have ... is part of the Department of Aging and Disability ... and disability services, supports and opportunities that are ...
(Date:5/21/2013)... France: One-year results from SOURCE XT one of ... to-date reported today at EuroPCR 2013 show good ... of device success for all access approaches, valve sizes ... followed up 2688 consecutively enrolled patients (mean age 81.5 ... at 93 centres in 17 countries between July 2010 ...
(Date:5/21/2013)... The In View series , a ... channels across the country, announces it has posted a ... producers of the series proudly bring audiences across the ... manufacturing industry, health-related companies, medical facilities and more. The ... in all parts of the United States, Canada and ...
(Date:5/21/2013)... May 21, 2013 Modern couples ... help of Texas Counseling’s Sexuality and Relationship Workshops, ... the development of healthier habits for their relationship. ... for both couples and individuals at Texas Counseling. ... relationships and learn skills to develop long term ...
(Date:5/21/2013)... for scientific and technological research So Paulo Research Foundation, ... an investment estimated in US$ 680 million to support ... period of up to eleven years, subject to continuation ... Funding for the 17 RIDCs will come from FAPESP ... personnel, and infrastructure). Host institutions will participate in a ...
Breaking Medicine News(10 mins):Health News:ContinuCare Home Health, Inc. Receives Perfect Report from the Texas Department of Aging and Disability Services 2Health News:In View hosted by Larry King Announces New Videos on its YouTube Channel 2Health News:Workshops Offered To Identify Underlying Challenges That Put Strain On Relationships 2Health News:Research at the cutting edge of knowledge 2
... pro-health messages can predict if you,ll keep that resolution ... That,s according to a new study forthcoming in ... who were already taking action to quit," says Emily ... of the Communication Neuroscience Laboratory at the U-M Institute ...
... to develop computer-assisted diagnosis tools that will provide ... consistently accurate diagnoses. "The advent of digital ... revolution in imaging technology for histopathology," according to ... Biomedical Informatics at The Ohio State University Medical ...
... the counter has not reduced the number of teenage ... sexually-transmitted diseases (STIs), according to a report by experts ... and Sourafel Girma used local health authority data to ... to offer emergency birth control at pharmacies and without ...
... Having sex while you,re pregnant is generally safe, a new ... review authors. "There are very few proven contraindications and risks ... be reassured." The primer, based on a review of ... Medical Association Journal . Some potential, but uncommon, risks ...
... to build an extra natural layer of nanoparticle-like armour has ... startlingly simple way to give drug bearing polymer vesicles (microscopic ... The Warwick researchers have been able to decorate these ... strategy in the design of vehicles for drug release, for ...
... Scientists have discovered why orchids are one of the most ... to their relationships with the bees that pollinate them and ... the American Naturalist , is the culmination of a ... College London, the Royal Botanic Gardens, Kew, and other international ...
Cached Medicine News:Health News:Resolved to quit smoking? 2Health News:Computer-assisted diagnosis tools to aid pathologists 2Health News:Computer-assisted diagnosis tools to aid pathologists 3Health News:Morning after pill linked to increase in STIs, study shows 2Health News:Morning after pill linked to increase in STIs, study shows 3Health News:Plankton inspires creation of stealth armor for slow-release microscopic drug vehicles 2Health News:Wealth of orchid varieties is down to busy bees and helpful fungi, says study 2Health News:Wealth of orchid varieties is down to busy bees and helpful fungi, says study 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: